Impact of Biotechnology in the Diagnostic and Therapeutic Management of Cardiovascular Disorders
Biotechnology has already exerted a major impact in the management of cardiovascular disorders by providing such drugs as tissue plasminogen activator (t-PA), urokinase, platelet targeting antibodies, recombinant anticoagulant agents such as hirudin and various modulatory proteins. On the diagnostic front, biotechnology has provided newer, more sensitive methods to detect minute changes in blood for the proper diagnosis and management of cardiovascular disorders. Several major breakthroughs in both the diagnosis and treatment of cardiovascular disorders have recently occurred. The measurement of troponin T and I in circulating blood provides a reliable measure of myocardial damage. Other analytes have also been identified for the rapid diagnosis of cardiovascular disorders. Such agents as tissue factor pathway inhibitor (TFPI), protein and antithrombin III have been developed and may prove to be useful in the management of antithrombotic disorders. Although the use of transgenic animals is still at experimental stages, the initial findings are promising and will provide important leads into the development of therapeutic proteins. Through biotechnology, recombinant inhibitors of fibrinolysis have also been developed and may be useful in the management of bleeding disorders. Nucleic acid derived drugs have been used for sometime. Several newer nucleic acid derivatives have been recently developed. An important consideration in the use of biotechnology derived drugs is the availability of a US Pharmacopoeial monograph on specific drugs. The subject of providing a monograph on biotechnology derived drugs is now being dealt with by the USP. Several other considerations in the development, clinical applications and the results of clinical trials on new biotechnology derived drugs are being addressed at this time. It is hoped that the impact of biotechnology on the diagnosis and treatment of cardiovascular disorders will result in a significant change in the management of these disorders.
KeywordsTissue Factor Cardiovascular Disorder Fibrin Clot Tissue Factor Pathway Inhibitor Specific Monoclonal Antibody
Unable to display preview. Download preview PDF.
- Bauer, K.A. and Rosenberg, R.D., 1987. The pathophysiology of the prothrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 70:343–350.Google Scholar
- Broze, G., Warren, J. and Novotnym L.A., 1988. The lipoprotein associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex also inhibits factors Xa: Insight into its possible mechanism of action, Blood 71:335–343.Google Scholar
- Farced, J., 1981, New methods in hemostatic testing. 1981, Perspectives in hemostasis. in “Perspectives in Hemostasis”. J. Fareed, ed., Pergamon Press, New York. NY.Google Scholar
- Fareed, J., Walenga, J.M. and Breddin, K., 1989. Newer avenues in antithrombotic therapy, Semin. Thromb. Hcmost. 15.Google Scholar
- Fareed, J., Walenga, J.M. and Hoppensteadt, D.A., 1988. Pharmacologic profiling of defibrotide in experimental models. Semin., Thromb. Hemost. 14:27–37.Google Scholar
- Fareed, J., Hoppensteadt, D., Walenga J.M. and Pifarre, R., 1993. New antithrombotic drugs for myocardial infarction in “Anticoagulation, Hemostasis and Blood Preservation in Cardiovascular Surgery”, R. Pifarre. ed., Hanley & Belfus. Philadelphia.Google Scholar
- Fareed, J., 1993a, Recombinant antithrombotic drugs. Impact on the management of thrombotic disorders in the 1990s. Proceedings in the International Biotechnology Exposition and Scientific Conference 1993), San Francisco. CA. pp. 50. 51. Cartlidge Associates. Belmont, CA.Google Scholar
- Fareed, J., Hoppensteadt, D., Walenga, J.M. and Bick, R.L., 1994, Current trends in the development of anticoagulant and antithrombotic drugs, Med. Clin. No. America 78:713–731.Google Scholar
- Fareed, J., 1994a, Proceedings of the International Biotechnology Exposition and Scientific Conference (IBEX 1994), San Francisco. CA. PP. 44. 46. 49. 50. 55. 67, Cartlidge Associates, Belmont, CA.Google Scholar
- Piascik, M.M., 1991. Research and development of drugs and biologic entities. Am. J. Hosp. Pharm. 48(10):S 4–13.Google Scholar
- Sidoli, A., Galliani, S. and Baralle, F.E., 1990. DNA based diagnostic tests: Recombinant DNA and cardiovascular disease risk factors. Br. Med. Bulletin 46(4):941–959.Google Scholar